Clinical Trial Update: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tinengotinib (TT-00420) for cholangiocarcinoma has completed; no efficacy or safety results are provided in the source snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• TT-00420 (Tinengotinib)

Snippet

Sponsor: TransThera Sciences (Nanjing), Inc. | Conditions: Cholangiocarcinoma, FGFR2 Fusion | Phase 2 | Status: COMPLETED